All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study
详细信息 查看全文
- 作者：Jia-Horng Kao ; Youn-Jae Lee ; Jeong Heo ; Sang-Hoon Ahn ; Young-Suk Lim ; Cheng-Yuan Peng ; Ting-Tsung Chang ; Anne Torbeyns ; Eric Hughes ; Rafia Bhore and Stephanie Noviello
- 刊名：Liver International
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：36
- 期：10
- 页码：1433-1441
- 全文大小：183K
- ISSN：1478-3231
文摘
Daclatasvir plus asunaprevir (DCV + ASV) has demonstrated potent antiviral activity in patients with hepatitis C virus (HCV) genotype 1b (GT-1b) infection in the HALLMARK DUAL trial. This post hoc analysis was conducted to determine the efficacy and safety of this treatment in Asian patients.